Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Schedule of Cash and Cash Equivalents [Table Text Block]

	D ecember 31, 201 7		September 3 0 , 201 8
Biolargo, Inc. and wholly owned subsidiaries	$	461,914	$	511,095
Clyra Medical Technologies, Inc.		528,543		22,447
Total	$	990,457	$	533,542

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

	September 30 , 2017			September 30 , 2018
Customer A		26	%		44	%
Customer B		11	%		12	%
Customer C		11	%		<10	%

	December 31, 2017			September 30 , 2018
Customer A		<10	%		23	%
Customer B		<10	%		17	%
Customer C		<10	%		10	%
Customer D		12	%		<10	%
Customer E		19	%		<10	%
Customer F		12	%		<10	%
Customer G		10	%		<10	%
Customer H		10	%		<10	%

Schedule of Inventory, Current [Table Text Block]

	D ecember 31, 2017		September 3 0 , 2018
Raw material	$	34,104	$	26,767
Finished goods		19,869		19,427
Total	$	53,973	$	46,194

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	T hree months September 30,						Nine months September 30,
	2017			2018			2017			2018
Revenues
Odor-No-More	$	172,045		$	245,979		$	318,040		$	785,929
BLEST		—			31,047			—			80,864
Consolidated revenue	$	172,045		$	277,026		$	318,040		$	866,793
Cost of goods/services
Odor-No-More	$	(123,278	)	$	(97,578	)	$	(219,207	)	$	(426,042	)
BLEST		—			(23,968	)		—			(59,608	)
Consolidated costs of goods/services	$	(123,278	)	$	(121,546	)	$	(219,207	)	$	(485,650	)
Net loss
Odor-No-More	$	(112,500	)	$	(111,963	)	$	(387,500	)	$	(365,651	)
BLEST		—			(63,555	)		—			(180,281	)
Clyra		(223,610	)		(219,971	)		(708,182	)		(596,333	)
BioLargo/Other		(1,910,016	)		(1,984,246	)		(6,050,186	)		(7,266,948	)
Consolidated net loss	$	(2,246,126	)	$	(2,379,735	)	$	(7,145,868	)	$	(8,409,213	)

	December		September
		31, 2017		30, 2018
Assets, net
Odor-No-More	$	210,725	$	231,216
BLEST		—		150,087
Clyra		528,543		25,807
BioLargo/Other		756,152		681,775
Consolidated assets, net	$	1,495,420	$	1,088,885